Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder
J Clin Psychiatry 2002;63(9):756-757
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Modern guidelines for psychopharmacologic treatment of anxiety disorders have evolved from recommending GABAergic (gammaaminobutryic acid) benzodiazepines to recommending serotonergic agents for first-line use. This trend, along with adverse publicity about the dependence potential of benzodiazepines, might lead one to suspect that benzodiazepines, once prominent in the 1980s but now generic and often disparaged, must have significantly declined in use. Not so. In fact, benzodiazepines are still more widely prescribed than antidepressants for the treatment of anxiety disorders (Table 1), and alprazolam is the single most commonly prescribed agent for mood and anxiety disorders(Table 2).